Gretchen Tamms

4.5k total citations
28 papers, 858 citations indexed

About

Gretchen Tamms is a scholar working on Epidemiology, Immunology and Microbiology. According to data from OpenAlex, Gretchen Tamms has authored 28 papers receiving a total of 858 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Epidemiology, 5 papers in Immunology and 4 papers in Microbiology. Recurrent topics in Gretchen Tamms's work include Pneumonia and Respiratory Infections (22 papers), Respiratory viral infections research (16 papers) and Pneumocystis jirovecii pneumonia detection and treatment (13 papers). Gretchen Tamms is often cited by papers focused on Pneumonia and Respiratory Infections (22 papers), Respiratory viral infections research (16 papers) and Pneumocystis jirovecii pneumonia detection and treatment (13 papers). Gretchen Tamms collaborates with scholars based in United States, Israel and Australia. Gretchen Tamms's co-authors include Emily Barr, John F. Modlin, Bruce G. Gellin, Luwy Musey, Eliav Barr, Tina M. Sterling, Ron Dagan, Ulrike K. Buchwald, Kathrin U. Jansen and Judith F. Smith and has published in prestigious journals such as PEDIATRICS, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Gretchen Tamms

27 papers receiving 825 citations

Peers

Countries citing papers authored by Gretchen Tamms

Since Specialization

Citations

This map shows the geographic impact of Gretchen Tamms's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gretchen Tamms with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gretchen Tamms more than expected).

Fields of papers citing papers by Gretchen Tamms

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gretchen Tamms. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gretchen Tamms. The network helps show where Gretchen Tamms may publish in the future.

Co-authorship network of co-authors of Gretchen Tamms

This figure shows the co-authorship network connecting the top 25 collaborators of Gretchen Tamms. A scholar is included among the top collaborators of Gretchen Tamms based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gretchen Tamms. Gretchen Tamms is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age 2025 ·Vaccines ·(unknown), (unknown), Aaron S. Weinberg, Spyros Chalkias, (unknown), Gretchen Tamms, Tina M. Sterling, (unknown), Tulin Shekar, Morgan Johnson, Natalie Banniettis, Ulrike K. Buchwald, Alejandra Esteves-Jaramillo	0
2	Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors 2023 ·Human Vaccines & Immunotherapeutics ·Laura L. Hammitt, Dean Quinn, Ewa Janczewska, Francisco J. Pasquel, Richard Tytus, K. Rajender Reddy, Katia Abarca, И. М. Хаертынова, Ron Dagan, Rachel Dawson, Jennifer McCauley, Tulin Shekar, (unknown), Alison Pedley, Tina M. Sterling, Gretchen Tamms, Luwy Musey, Ulrike K. Buchwald	4
3	A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM) 2023 ·Clinical Infectious Diseases ·Marissa B. Wilck, Oliver A. Cornely, Catherine Cordonnier, Juan D. Vélez, Per Ljungman, Johan Maertens, Dominik Selleslag, Kathleen M. Mullane, Samir Nabhan, (unknown), Ron Dagan, Peter Richmond, (unknown), (unknown), Gretchen Tamms, Tina M. Sterling, (unknown), Tulin Shekar, Luwy Musey, Ulrike K. Buchwald, (unknown)	6
4	A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED) 2023 ·Vaccine ·Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, Jake D. Jones, (unknown), Betül Ulukol, Ron Dagan, Peter Richmond, Jon E. Stek, (unknown), Sandra Koseoglu, Gretchen Tamms, Richard McFetridge, Jianing Li, (unknown), Luwy Musey, Natalie Banniettis, Kara Bickham	26
5	PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children 2023 ·Expert Review of Vaccines ·Timothy J. Chapman, Liset Olarte, Ghassan Dbaibo, Avril Melissa Houston, Gretchen Tamms, Robert Lupinacci, Kristen A. Feemster, Ulrike K. Buchwald, Natalie Banniettis	11
6	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study 2022 ·Blood Advances ·Charles T. Quinn, Richard T. Wiedmann, Daniel Jarovsky, Eduardo López‐Medina, (unknown), (unknown), (unknown), Qiong Shou, Ron Dagan, Peter Richmond, Kristen A. Feemster, Richard McFetridge, Gretchen Tamms, Robert Lupinacci, Luwy Musey, Kara Bickham	6
7	Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE) 2022 ·Vaccine ·Jakub K. Simon, Nina Breinholt Stærke, (unknown), (unknown), Ron Dagan, Tulin Shekar, Alison Pedley, Patricia Jumes, Gretchen Tamms, Tina M. Sterling, Luwy Musey, Ulrike K. Buchwald	8
8	Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial 2022 ·The Lancet Infectious Diseases ·Heather Platt, (unknown), José F. Cardona, Neil J. Fraser, Richard A. Mularski, Charles M. Andrews, Nizar Daboul, Nancy Gallagher, Aditi Sapre, Jianing Li, Adam B. Polis, Doreen Fernsler, Gretchen Tamms, Weifeng Xu, (unknown), Julie M. Skinner, Joseph G. Joyce, Luwy Musey	52
9	A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION) 2022 ·Vaccine ·Androniki Bili, Scott Dobson, (unknown), Wanatpreeya Phongsamart, Peninnah Oberdorfer, Pope Kosalaraksa, Ron Dagan, Peter Richmond, Marissa B. Wilck, (unknown), (unknown), Richard McFetridge, Gretchen Tamms, Rong Fu, Robert Lupinacci, Luwy Musey, Natalie Banniettis, Kara Bickham	10
10	A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN) 2022 ·Vaccine ·Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, Wanatpreeya Phongsamart, Punnee Pitisuttithum, (unknown), Peter Richmond, (unknown), Ron Dagan, (unknown), (unknown), Robert Lupinacci, Richard McFetridge, Gretchen Tamms, (unknown), Luwy Musey, Kara Bickham	11
11	Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older 2021 ·Human Vaccines & Immunotherapeutics ·Ulrike K. Buchwald, Charles P. Andrews, John Ervin, James T. Peterson, Gretchen Tamms, David Krupa, (unknown), Lucy Roalfe, (unknown), Tina M. Sterling, Meihua Wang, Jason Martin, Jon E. Stek, Melvin A. Kohn, Temitope Folaranmi, Chitrananda Abeygunawardana, Jonathan Hartzel, Luwy Musey, (unknown)	10
12	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH) 2021 ·Vaccine ·Joon Young Song, Chih‐Jen Chang, Charles P. Andrews, Javier Díez‐Domingo, Myoung‐don Oh, Ron Dagan, Jonathan Hartzel, Alison Pedley, Jianing Li, Tina M. Sterling, Gretchen Tamms, (unknown), (unknown), Luwy Musey, (unknown), Ulrike K. Buchwald	31
13	A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE) 2021 ·Vaccine ·Heather Platt, José F. Cardona, Miwa Haranaka, Howard I. Schwartz, Silvia Narejos Pérez, Anthony Dowell, Chih‐Jen Chang, Ron Dagan, Gretchen Tamms, Tina M. Sterling, (unknown), (unknown), Alison Pedley, Luwy Musey, Ulrike K. Buchwald	64
14	1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors 2021 ·Open Forum Infectious Diseases ·Laura L. Hammitt, Dean Quinn, Ewa Janczewska, Francisco J. Pasquel, Richard Tytus, K. Rajender Reddy, Katia Abarca, И. М. Хаертынова, Ron Dagan, Rachel Dawson, Jennifer McCauley, (unknown), Alison Pedley, Tina M. Sterling, Gretchen Tamms, Luwy Musey, Ulrike K. Buchwald	1
15	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV 2021 ·AIDS ·Lerato Mohapi, (unknown), Olayemi Osiyemi, Khuanchai Supparatpinyo, Winai Ratanasuwan, Jean‐Michel Molina, Ron Dagan, Gretchen Tamms, Tina M. Sterling, Ying Zhang, Alison Pedley, (unknown), Yanqing Kan, (unknown), Luwy Musey, Jakub K. Simon, Ulrike K. Buchwald	19
16	Phase 1 Clinical Trial of a Replication-Defective Human Cytomegalovirus (CMV) Vaccine 2017 ·Open Forum Infectious Diseases ·Stuart P. Adler, Nicole Lewis, (unknown), Mark P. Christiansen, Mohamed Al‐Ibrahim, Richard Rupp, Tong‐Ming Fu, Oliver Bautista, Huaping Tang, Timothy D. Culp, Rituparna Das, Karen Beck, Gretchen Tamms, Luwy Musey	5
17	Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine 2010 ·The Pediatric Infectious Disease Journal ·Stan L. Block, Darron R. Brown, Archana Chatterjee, Michael A. Gold, Heather L. Sings, Anne R. Meibohm, Adrian Dana, Richard M. Haupt, Eliav Barr, Gretchen Tamms, (unknown), Keith S. Reisinger	84
18	Quadrivalent Human Papillomavirus Vaccine 2007 ·Clinical Infectious Diseases ·Bruce G. Gellin, John F. Modlin, Emily Barr, Gretchen Tamms	255
19	Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial 2005 ·Mayo Clinic Proceedings ·Gregory A. Poland, Robert M. Jacobson, Laura A. Koutsky, Gretchen Tamms, Radha Railkar, Judith F. Smith, Janine T. Bryan, Paul F. Cavanaugh, Kathrin U. Jansen, Eliav Barr	47
20	A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine 2004 ·Vaccine ·Kevin A. Ault, Anna R. Giuliano, Robert P. Edwards, Gretchen Tamms, (unknown), Judith F. Smith, Kathrin U. Jansen, Maria C. Allende, Frank J. Taddeo, (unknown), Eliav Barr	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact